Joel Block to Antibodies, Monoclonal
This is a "connection" page, showing publications Joel Block has written about Antibodies, Monoclonal.
Connection Strength
1.311
-
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):85-87.
Score: 0.535
-
Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
Score: 0.386
-
Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther. 2008 Jan-Feb; 15(1):53-8.
Score: 0.273
-
New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol. 2007 May; 19(3):259-64.
Score: 0.065
-
Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother. 2009 Mar; 58(3):339-49.
Score: 0.018
-
Antinucleic acid autoantibody responses of normal human origin: antigen specificity and idiotypic characteristics compared to patients with systemic lupus erythematosus and patients with monoclonal IgM. J Rheumatol Suppl. 1987 Jun; 14 Suppl 13:127-31.
Score: 0.016
-
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 01; 39(3):295-9.
Score: 0.013
-
Clonal analysis of human chondrosarcoma. Chir Organi Mov. 1990; 75(1 Suppl):11-3.
Score: 0.005